MNPR Stock Overview A clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. More details
Rewards Risk Analysis See All Risk Checks {"enabled":false,"variant":{"name":"disabled","enabled":false},"ready":false,"error":null}
Capture your thoughts, links and company narrative
Monopar Therapeutics Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Monopar Therapeutics Historical stock prices Current Share Price US$50.52 52 Week High US$54.30 52 Week Low US$1.65 Beta 1.31 1 Month Change 96.65% 3 Month Change 177.13% 1 Year Change 2,894.67% 3 Year Change 237.93% 5 Year Change -9.40% Change since IPO -61.87%
Recent News & Updates
New minor risk - Profitability Jan 10
Forecast to breakeven in 2027 Dec 31 Monopar Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $19.000002 million. Dec 21
Monopar Therapeutics Inc. Doses First Patient with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu Dec 06
Price target increased by 51% to US$27.33 Nov 20 Monopar Therapeutics Inc. has completed a Follow-on Equity Offering in the amount of $19.200025 million. Oct 31
See more updates
New minor risk - Profitability Jan 10
Forecast to breakeven in 2027 Dec 31 Monopar Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $19.000002 million. Dec 21
Monopar Therapeutics Inc. Doses First Patient with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu Dec 06
Price target increased by 51% to US$27.33 Nov 20 Monopar Therapeutics Inc. has completed a Follow-on Equity Offering in the amount of $19.200025 million. Oct 31
New major risk - Shareholder dilution Oct 30 Monopar Therapeutics Inc. has filed a Follow-on Equity Offering. Oct 29
Monopar Expands Radiopharma Intellectual Property Portfolio with Patent Filing on New Compounds and Linkers Oct 16
Monopar Therapeutics Inc. Initiates Clinical Trial of Novel uPAR-Targeted Radiopharmaceutical Therapy in Advanced Cancers Oct 07
Monopar Regains Compliance with Nasdaq Minimum Bid Price Rule Aug 28
Monopar Receives Clearance to Proceed with Phase 1 Therapeutic Trial of Novel Radiopharmaceutical in Advanced Cancers Aug 22
Monopar Receives Clearance to Proceed with Phase 1 Therapeutic Trial of Novel Radiopharmaceutical in Advanced Cancers Aug 21
Monopar Therapeutics Inc. Announces Initial Data for First Patient Dosed in Radiopharma Phase 1 Clinical Trial of MNPR-101-Zr Aug 14
We Think Monopar Therapeutics (NASDAQ:MNPR) Needs To Drive Business Growth Carefully Aug 13
New major risk - Market cap size Aug 09
New major risk - Financial position Jul 25
New major risk - Revenue and earnings growth Jul 17
Monopar Therapeutics Inc., Annual General Meeting, Aug 05, 2024 Jul 13
Monopar Therapeutics Inc. Announces First Patient Enrolled in First-in-Human Phase 1 Trial for Its Novel Radiopharmaceutical MNPR-101-Zr Jul 09
Monopar Therapeutics Inc. Announces CFO Changes May 26 Monopar Therapeutics Inc. Announces CFO Changes May 25
Price target decreased by 38% to US$2.08 May 12
Monopar Therapeutics Inc. Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings Apr 16
Monopar Therapeutics Inc Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients Apr 10
Price target decreased by 52% to US$4.05 Apr 01
Monopar Therapeutics Inc. Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program Mar 05
Nasdaq Grants Extension to Monopar Therapeutics to Regain Compliance with the Minimum Bid Price Requirement Feb 29
Is Monopar Therapeutics (NASDAQ:MNPR) In A Good Position To Deliver On Growth Plans? Feb 27
Monopar Therapeutics Inc. Announces Promising Preclinical Data for its MNPR-101 Radiopharma Program Targeting Advanced Cancers Feb 23
Monopar Receives Clearance to Proceed with First-In-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancers Feb 20
New major risk - Share price stability Dec 09
New major risk - Share price stability Nov 07
Monopar Therapeutics Inc. Presents Data Showing Tumor Reduction Benefit of Camsirubicin from Ongoing Phase 1b at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting Nov 02
Monopar Therapeutics Receives Letter from Nasdaq Regarding Bid Price Requirement Sep 01
Monopar Therapeutics Receives Letter from Nasdaq Regarding Bid Price Requirement Aug 31
New major risk - Revenue and earnings growth Aug 15
New major risk - Revenue and earnings growth Aug 11
Monopar Therapeutics Inc. Provides Update on Camsirubicin Clinical Trial Aug 09
New major risk - Market cap size Jul 26
Monopar Therapeutics Inc. Announces Encouraging Camsirubicin Phase 1b Trial Update Jun 02
Price target decreased by 49% to US$9.80 Mar 29
Will Monopar Therapeutics (NASDAQ:MNPR) Spend Its Cash Wisely? Mar 02
Monopar Therapeutics Inc. Announces Camsirubicin Clinical Program Update - Improved Side Effect Profile Seen to Date Compared to Doxorubicin Feb 15
Monopar Therapeutics Inc. Announces Projected Timeline of Upcoming Quarter 1 2023 Data Events for Validive, Camsirubicin, and MNPR-101 RIT Jan 28
Price target increased by 12% to US$19.29 Jan 24
Monopar Therapeutics Inc. Announces Successful Advancement of Camsirubicin Phase 1b Clinical Trial Past Fourth Cohort, Escalates Next to 650mg/m2 Jan 19
Monopar Therapeutics Inc. Announces Promising MNPR-202 Data from Ongoing National University of Singapore Collaboration Dec 13
Monopar Therapeutics Inc. Announces Encouraging Clinical Data from Ongoing Camsirubicin Phase 1B Trial Nov 17
We Think Monopar Therapeutics (NASDAQ:MNPR) Needs To Drive Business Growth Carefully Nov 16
Insufficient new directors Nov 16
Monopar Announces Completion of Phase 2b Enrollment and Commencement of Phase 3 Enrollment in Its Voice Trial for Severe Oral Mucositis Oct 06
Monopar stock soars 19% as enrollment finishes in phase 2 part of oral mucositis study of Validive Oct 05
Price target increased to US$32.67 Aug 04
We're Keeping An Eye On Monopar Therapeutics' (NASDAQ:MNPR) Cash Burn Rate Jul 30
Monopar Therapeutics Inc., Annual General Meeting, Jun 28, 2022 May 02
Insufficient new directors Apr 27
Monopar Therapeutics Announces Resignation of Andrew P. Mazar as Member of the Board of Directors, Effective April 8, 2022 Apr 03
Monopar Therapeutics (NASDAQ:MNPR) Is In A Good Position To Deliver On Growth Plans Mar 28
Monopar Announces Clinical and Preclinical Program Updates Feb 16
Price target increased to US$32.67 Feb 03
Monopar Therapeutics Inc. Advances Dosing of Camsirubicin to Higher Level Than Tested In Any Previous Clinical Trial Dec 10
Price target increased to US$33.33 Nov 16
Monopar Therapeutics Inc. Expands Phase 2b/3 VOICE Clinical Trial to Europe Sep 14
Monopar Therapeutics Inc. Announces FDA Clearance to Proceed with Camsirubicin Clinical Trial Targeting Advanced Soft Tissue Sarcoma Aug 05
We're Hopeful That Monopar Therapeutics (NASDAQ:MNPR) Will Use Its Cash Wisely Jul 15
Monopar Therapeutics Inc. to Present Results from Analysis of Oropharyngeal Cancer Patients in Completed Phase 2 Validive® Trial At MASCC/ISOO Jun 25
Monopar Therapeutics Inc. and Northstar Medical Radioisotopes Announce Patent Filing on Promising Radiopharmaceutical Discovery May 25
Forecast to breakeven in 2025 May 18
Here's Why We're Not Too Worried About Monopar Therapeutics' (NASDAQ:MNPR) Cash Burn Situation Mar 26
Monopar Therapeutics Inc. Appoints Laura Kelly as Director of Clinical Operations Feb 19
Monopar Announces First Patient Dosed in Its Phase 2b/3 VOICE Trial Evaluating Validive® for the Prevention of Chemoradiotherapy-Induced Severe Oral Mucositis (SOM) in Oropharyngeal Cancer (OPC) Feb 18
Monopar Announces Publication Demonstrating Potential Utility of MNPR-101 as an Imaging Agent to Improve Surgical Outcomes in Bladder Cancer Feb 13
New 90-day high: US$8.51 Jan 29
Price target raised to US$33.33 Jan 29
Monopar nabs U.S. patent covering camsirubicin Dec 22
Monopar Therapeutics Inc. and NorthStar Medical Radioisotopes, LLC Announces Selection of uPRIT Candidate for Potential Treatment of Severe COVID-19 Dec 13
Monopar Therapeutics selects targeted immuno-therapeutic candidate for COVID-19 Dec 10
New 90-day high: US$5.66 Dec 10
Monopar launches validive mid-stage study in chemo-induced oral mucositis Dec 08
Monopar Therapeutics EPS beats by $0.02 Nov 12
New 90-day low: US$4.43 Nov 04
New 90-day low: US$4.86 Oct 20
New 90-day low: US$4.98 Sep 24
New 90-day low - US$4.98 Sep 04
New 90-day low - US$6.05 Aug 14
Monopar Therapeutics Inc.(NasdaqCM:MNPR) dropped from Russell Microcap Value Index Jul 02 Shareholder Returns MNPR US Biotechs US Market 7D 3.6% -4.2% 0.2% 1Y 2,894.7% -3.0% 23.1%
See full shareholder returns
Return vs Market: MNPR exceeded the US Market which returned 23.1% over the past year.
Price Volatility Is MNPR's price volatile compared to industry and market? MNPR volatility MNPR Average Weekly Movement 17.8% Biotechs Industry Average Movement 11.4% Market Average Movement 5.9% 10% most volatile stocks in US Market 18.3% 10% least volatile stocks in US Market 3.0%
Stable Share Price: MNPR's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: MNPR's weekly volatility has decreased from 90% to 18% over the past year, but is still higher than 75% of US stocks.
About the Company Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops MNPR-101-Zr, a clinical stage urokinase plasminogen activator receptor-targeted radiodiagnostic imaging agent; and MNPR-101-RIT, a late preclinical stage radiotherapeutic for advanced cancers. It also develops Camsirubicin, a Phase 1b clinical stage novel analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; and MNPR-202, an analog of Camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers.
Show more Monopar Therapeutics Inc. Fundamentals Summary How do Monopar Therapeutics's earnings and revenue compare to its market cap? MNPR fundamental statistics Market cap US$313.03m Earnings (TTM ) -US$6.47m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) MNPR income statement (TTM ) Revenue US$0 Cost of Revenue US$0 Gross Profit US$0 Other Expenses US$6.47m Earnings -US$6.47m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/02/12 22:41 End of Day Share Price 2025/02/12 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github .
Analyst Sources Monopar Therapeutics Inc. is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Kumaraguru Raja Brookline Capital Markets Brian Kemp Dolliver Brookline Capital Markets Sean Lee H.C. Wainwright & Co.
Show 4 more analysts 
